Jonathan Willis, MD
Family Medicine · Waco, TXNPI 1437538162
Payments from drug & device makers
Across 729 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$1K
- GSK$1K
- Amgen$1K
- Lilly USA, LLC$937
- AbbVie$882
- plus $6K from 31 others
What the payments were for
- Food & beverage$12,142100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 63 | $1,318 |
| Novo Nordisk | 63 | $1,173 |
| GSK | 60 | $1,165 |
| Amgen | 67 | $1,032 |
| Lilly USA, LLC | 72 | $937 |
| AbbVie(2 entities) | 71 | $882 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 53 | $685 |
| Sanofi-aventis U.S. LLC | 34 | $547 |
| Pfizer | 33 | $519 |
| Merck | 33 | $468 |
| Boehringer Ingelheim | 24 | $403 |
| Sumitomo Pharma America, Inc. | 12 | $370 |
| Amarin Pharma, Inc. | 21 | $350 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $289 |
| Exact Sciences | 14 | $225 |
| Astellas Pharma US Inc | 8 | $222 |
| Kowa Pharmaceuticals America, Inc. | 15 | $212 |
| Idorsia Pharmaceuticals US Inc | 14 | $210 |
| Phathom Pharmaceuticals, Inc. | 12 | $188 |
| Abbott | 7 | $144 |
| Esperion Therapeutics, Inc. | 7 | $117 |
| Genentech USA, Inc. | 7 | $108 |
| Nevro Corp. | 1 | $84 |
| Sunovion Pharmaceuticals Inc. | 5 | $81 |
| Corium, LLC | 3 | $67 |
| Novartis | 3 | $52 |
| Bayer | 3 | $51 |
| Johnson & Johnson | 2 | $36 |
| Dexcom, Inc. | 2 | $35 |
| Organon | 2 | $33 |
| Eisai Inc. | 2 | $30 |
| Coastal Medical Technologies LLC | 1 | $30 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,154 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 78 | $94,092 |
| EliquisApixaban | 78 | $75,321 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $55,329 |
| JardianceEmpagliflozin | 61 | $50,591 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 34 | $44,123 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $40,182 |
| MounjaroTirzepatide | 36 | $36,704 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 30 | $36,072 |
| CreonLipase/Protease/Amylase | 13 | $33,383 |
| XareltoRivaroxaban | 35 | $29,243 |
| MyrbetriqMirabegron | 38 | $23,792 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $23,115 |
| FarxigaDapagliflozin Propanediol | 19 | $22,295 |
| GemtesaVibegron | 12 | $13,325 |
| Atorvastatin Calcium | 862 | $10,082 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr | $403 | $94,71495 claims |
| Novo NordiskOzempic | $1,173 | $94,09278 claims |
| PfizerEliquis | $519 | $75,32178 claims |
| GSKTrelegy Ellipta | $1,165 | $55,32960 claims |
| Lilly USA, LLCMounjaro | $937 | $36,70436 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $547 | $36,07230 claims |
| AbbVieCreon | $882 | $33,38313 claims |
| AstraZenecaFarxiga, Symbicort | $1,318 | $29,35933 claims |
| Johnson & JohnsonXarelto | $36 | $29,24335 claims |
| Astellas Pharma US IncMyrbetriq | $222 | $23,79238 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $370 | $13,32512 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $212 | $3,73812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Waco
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.